PHILADELPHIA Based on research using a new mouse model of gastritis and stomach cancer, researchers from the Massachusetts Institute of Technology (MIT) say that prompt treatment of Helicobacter pylori (H. pylori) infections reverses damage to the lining of the stomach that can lead to cancer.
In the May 1 issue of Cancer Research, a journal of the American Association for Cancer Research, researchers say their study results should lay to rest any question about whether and when - antibiotic treatment of H. pylori can eliminate or reduce risk of developing gastric, or stomach cancer.
We concluded that H. pylori eradication prevented gastric cancer to the greatest extent when antibiotics were given at an early point of infection, but that eradication therapy given at a later time point also delayed the development of severe lesions that can lead to cancer, said the studys lead author, James G. Fox, D.V.M., professor and director of the Division of Comparative Medicine at MIT.
The findings are important, Fox says, because stomach cancer is the second leading cause of cancer death worldwide, and approximately half of the worlds population is infected with H. pylori. Although H. pylori infection is now recognized as the major cause of both peptic ulcers and gastric cancer, and has been classified as a group I carcinogen by the World Health Organization, physicians are not sure whom to screen and treat with costly antibiotics, aside from first degree relatives of gastric cancer patients and those with peptic ulcer disease, he adds.
Since it typically takes several decades for gastric cancer to develop in those who are susceptible which is estimated to be up to three percent of infected people researchers also do not know when to treat the infection for maximum benefit. Human studies that tested treatment in patients who had already developed tumors had mixed results, but one previous study showed that giving antibiotics befo
|Contact: Jeremy Moore|
American Association for Cancer Research